Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) shares saw strong trading volume on Monday . 138,129 shares traded hands during mid-day trading, an increase of 12% from the previous session's volume of 123,643 shares.The stock last traded at $9.98 and had previously closed at $9.99.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday, May 14th. Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price objective on the stock in a research note on Friday, March 14th. Jefferies Financial Group upgraded Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their target price for the stock from $1.00 to $2.00 in a report on Friday, April 11th. HC Wainwright reaffirmed a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a research note on Thursday, March 13th. Finally, William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $4.50.
Get Our Latest Analysis on NKTR
Nektar Therapeutics Stock Down 11.4%
The company has a fifty day moving average price of $0.66 and a 200 day moving average price of $0.83. The stock has a market cap of $1.65 billion, a PE ratio of -10.57 and a beta of 0.55.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). The company had revenue of $10.46 million during the quarter, compared to analysts' expectations of $15.61 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. During the same period last year, the firm earned ($0.18) earnings per share. As a group, research analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current year.
Institutional Investors Weigh In On Nektar Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its stake in shares of Nektar Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 11,681 shares during the last quarter. Moloney Securities Asset Management LLC grew its position in shares of Nektar Therapeutics by 42.4% in the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company's stock worth $46,000 after buying an additional 14,895 shares during the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth approximately $1,030,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Nektar Therapeutics by 12.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 730,875 shares of the biopharmaceutical company's stock valued at $680,000 after buying an additional 80,034 shares during the period. Finally, Monaco Asset Management SAM raised its holdings in shares of Nektar Therapeutics by 1.8% during the fourth quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company's stock valued at $1,891,000 after acquiring an additional 35,648 shares in the last quarter. Institutional investors own 75.88% of the company's stock.
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
